IN8bio, Inc., a pioneering clinical-stage biopharmaceutical company, recently announced a groundbreaking milestone in the Phase 1 trial of INB-200 for newly-diagnosed GBM. Patient 009, with a grade 4, IDH-mutant glioma, has achieved an impressive 4-year remission after treatment with INB-200. This exceptional outcome, far surpassing typical progression-free rates, highlights the potential of gamma-delta T cell therapies in combating aggressive cancers. Dr. Burt Nabors, Principal Investigator of the trial, emphasized the significance of this achievement, underscoring the promising impact of INB-200 in challenging cancer cases.
The latest data presented at the 2025 ASCO Annual Meeting revealed that repeated administration of INB-200 extended mPFS to 16.1 months, showcasing superior efficacy compared to standard-of-care treatments. IN8bio’s innovative approach utilizing genetically modified gamma-delta T cells demonstrates a favorable safety profile and long-term benefits, offering new hope in the fight against GBM. CEO William Ho expressed excitement over the remarkable milestone, emphasizing the company’s commitment to transforming cancer treatment outcomes. IN8bio’s focus on developing gamma-delta T cell-based therapies for cancer and autoimmune diseases signifies a significant advancement in immunotherapy. With a robust pipeline and a dedication to pioneering novel treatment modalities, IN8bio continues to push the boundaries of medical innovation.
Read more from finanznachrichten.de